Wintest
6721
Showcase
3909
Beauty Kadan Holdings
3041
Cybozu
4776
KODAMA CHEMICAL INDUSTRY
4222
JP Stock MarketDetailed Quotes
4576 D. Western Therapeutics Institute
- 225
- -10-4.26%
20min DelayMarket Closed Dec 20 15:30 JST
8.54BMarket Cap-8.80P/E (Static)
254High200Low22.07MVolume226Open235Pre Close5.12BTurnover25452wk High74.12%Turnover Ratio37.98MShares6052wk Low-33.82EPS TTM6.70BFloat Cap3755Historical HighLossP/E (Static)29.78MShs Float59Historical Low-25.56EPS LYR22.98%Amplitude--Dividend TTM9.98P/B100Lot Size--Div YieldTTM
D. Western Therapeutics Institute Key Stats
Quarterly+Annual
YOY
| (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 21.49%118.7M | 16.47%104.82M | -4.40%428.36M | -17.69%114.37M | 27.40%126.28M | -2.60%97.71M | -17.97%90M | 8.13%448.1M | 41.01%138.94M | -13.28%99.12M |
| Cost of revenue | 27.67%9.4M | 24.51%9.13M | 33.01%36.67M | 4.42%8.94M | 121.59%13.03M | 20.24%7.37M | 4.71%7.33M | 37.15%27.57M | 51.25%8.56M | 10.90%5.88M |
| Gross profit | 20.98%109.3M | 15.75%95.69M | -6.86%391.7M | -19.14%105.43M | 21.46%113.25M | -4.08%90.35M | -19.52%82.67M | 6.65%420.53M | 40.39%130.38M | -14.45%93.24M |
| Operating expense | -2.93%240.35M | 125.57%414.49M | 63.85%1.19B | 141.57%446.35M | 47.15%312.54M | 31.31%247.61M | 30.59%183.75M | 28.35%726.45M | 23.06%184.77M | 60.74%212.4M |
| Research and development costs | -3.88%174.54M | 206.48%346.86M | 98.16%930.51M | 225.92%384.89M | 65.36%250.86M | 46.67%181.58M | 48.97%113.18M | 48.52%469.56M | 34.14%118.09M | 99.45%151.7M |
| Other operating expenses | -0.34%65.81M | -4.19%67.62M | 1.12%259.75M | -7.83%61.46M | 1.62%61.68M | 1.95%66.04M | 9.03%70.58M | 2.83%256.88M | 7.34%66.68M | 8.23%60.69M |
| Operating profit | 16.67%-131.05M | -215.37%-318.8M | -161.04%-798.56M | -526.81%-340.92M | -67.25%-199.29M | -66.64%-157.27M | -166.08%-101.09M | -78.22%-305.91M | 5.05%-54.39M | -414.86%-119.16M |
| Net non-operating interest income (expenses) | -954.20%-9.92M | 32.68%-865K | 73.87%-3.88M | 57.10%-674K | 85.92%-976K | 82.76%-941K | -47.19%-1.29M | -166.31%-14.84M | -59.65%-1.57M | -210.94%-6.93M |
| Non-operating interest income | --0 | -33.33%4K | -60.00%10K | --0 | -66.67%4K | --0 | -53.85%6K | 19.05%25K | --0 | 0.00%12K |
| Non-operating interest expense | 106.01%1.23M | 38.82%869K | -20.88%2.49M | -1.17%674K | -21.72%591K | -27.31%599K | -29.35%626K | -28.87%3.15M | -30.69%682K | -29.70%755K |
| Total other finance cost | ---- | ---- | -88.08%1.4M | --0 | -93.72%389K | --342K | --665K | 902.91%11.71M | --889K | --6.19M |
| Net investment income | -39.16%3.09M | 120.23%2.65M | -79.83%6.71M | 84.79%-681K | -77.33%1.12M | -75.88%5.07M | -89.81%1.2M | 91.45%33.28M | -199.14%-4.48M | 208.11%4.94M |
| Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
| Gain(Loss) on derecognition of available-for-sale financial assets | 87.05%-12.99M | -100.32M | ||||||||
| Income from associates and other participating interests | ||||||||||
| Special income (charges) | 60.47%-17.45M | -44.14M | ||||||||
| Less:Other special charges | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --44.14M | ---- | ---- |
| Less:Write off | ---- | ---- | --17.45M | ---- | ---- | ---- | ---- | --0 | ---- | ---- |
| Other non-operating income (expenses) | -660.80%-951K | -2,035.40%-3.44M | 92.30%-642K | -103.46%-140K | -58.82%-216K | 99.05%-125K | -116.50%-161K | -6,663.78%-8.34M | 8,348.98%4.04M | -500.00%-136K |
| Income before tax | -30.14%-199.45M | -216.25%-320.45M | -87.80%-826.8M | -85.63%-372.86M | -64.37%-199.36M | -66.56%-153.26M | -288.13%-101.33M | -175.66%-440.27M | -273.37%-200.86M | -410.97%-121.29M |
| Income tax | 0.00%399K | 0.00%398K | 0.00%1.6M | 0.00%399K | 0.00%399K | 0.00%399K | 0.00%398K | 0.00%1.6M | 0.00%399K | 0.00%399K |
| Net income | -30.06%-199.84M | -215.40%-320.85M | -87.48%-828.4M | -85.46%-373.25M | -64.16%-199.76M | -66.27%-153.66M | -283.80%-101.73M | -173.93%-441.86M | -271.37%-201.26M | -404.15%-121.69M |
| Net income continuous operations | -30.06%-199.85M | -215.40%-320.85M | -87.48%-828.4M | -85.46%-373.26M | -64.16%-199.76M | -66.28%-153.66M | -283.81%-101.73M | -173.93%-441.86M | -271.36%-201.26M | -404.17%-121.69M |
| Noncontrolling interests | 0 | 0 | -31.29%-15.99M | -342.94%-4.76M | 33.01%-3.82M | 6.75%-3.54M | 16.73%-3.87M | 1.09%-12.18M | 127.58%1.96M | -5.7M |
| Net income attributable to the company | -33.12%-199.84M | -227.87%-320.85M | -89.07%-812.41M | -81.33%-368.49M | -68.93%-195.94M | -69.40%-150.12M | -347.65%-97.86M | -188.39%-429.69M | -331.60%-203.22M | -512.55%-115.99M |
| Preferred stock dividends | ||||||||||
| Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income attributable to common stockholders | -33.12%-199.84M | -227.87%-320.85M | -89.07%-812.41M | -81.33%-368.49M | -68.93%-195.94M | -69.40%-150.12M | -347.65%-97.86M | -188.39%-429.69M | -331.60%-203.22M | -512.55%-115.99M |
| Gross dividend payment | ||||||||||
| Basic earnings per share | -29.68%-6.16 | -218.15%-9.99 | -76.28%-25.56 | -69.71%-11.54 | -55.58%-6.13 | -57.28%-4.75 | -324.32%-3.14 | -185.43%-14.5 | -325.00%-6.8 | -506.15%-3.94 |
| Diluted earnings per share | -29.68%-6.16 | -218.15%-9.99 | -76.28%-25.56 | -69.71%-11.54 | -55.58%-6.13 | -57.28%-4.75 | -324.32%-3.14 | -185.43%-14.5 | -323.99%-6.8 | -506.15%-3.94 |
| Dividend per share | ||||||||||
| Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
| Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |